BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today announced that the investigational B7-H3 ...

MiNK ended the quarter with a cash balance of $3.2 million. Cash used in operations for the three months ended March 31, 2025 ...

Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...

Like cancer, placental cells multiply rapidly, invade tissues, and evade destruction by the immune system, but maternal ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...

HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD ...

A small but powerful clinical trial reveals that resveratrol and copper can reduce tumor growth, restore immune function, and ...

Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

Cryptic peptides, which are expressed in pancreatic cancer cells, could be promising targets for T-cell therapies that attack pancreatic tumors, according to a new study.

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...